Otsuka America Pharmaceutical のニュースと活動
存在感
Otsuka Holdingsはの一部です...
％sは、株式相場表示 ％s（％s）の下にリストされている会社です。
Otsuka Holdings は 10 の国に直接拠点を置いています。Otsuka HoldingsはAstex,Astex Pharmaceuticals,Cambridge Isotope Laboratoriesを含む25の子会社があります。
彼らはにいます：
役員
25人の主要幹部と一緒に組織図を見る
Otsuka America Pharmaceuticalでもっとも検索された略歴
- Tarek Rabah, President and Chief Executive Officer
- Steve Rosen, Vice President and Chief Financial Officer
- Nick Kurahashi, Executive Vice President, Global Pharmaceutical St...
アラートを作成
Otsuka America Pharmaceutical のエグゼクティブの異動をフォローします。
医薬品
Otsuka HoldingsはPfizer (アメリカ合衆国（米国）),Sanofi (フランス共和国),Eli Lilly (アメリカ合衆国（米国）)を含む1,833の競合企業を有します。
Popular M&A news in 医薬品
- ％sは、％s百万ドルの資金調達を発表しました。 (2025年4月10日に公開).
- ％2$sは％1 $ sを取得しました (2025年3月18日に公開).
- Knight Therapeutics has announced the acquisition of Paladin Labs (2025年3月12日に公開).
医薬品業界でのその他のコンタクトの提案
ニュース
％sによる最新のプレスリリース
- Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease | Otsuka US
- FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults | Otsuka US
- Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder | Otsuka US
- Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer’s Dementia | Otsuka US
- Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as Aripiprazole 1-Month for Treatment of Schizophrenia and Bipolar I Disorder | Otsuka
- Otsuka and Verily Expand Collaboration on Novel Clinical Trials Solutions to Accelerate Research in Major Depressive Disorder | Otsuka US
- Otsuka and Lundbeck announce FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia | Otsuka US
- Otsuka Pharmaceutical and Lundbeck Present Positive Data From Multiple Phase 3 Studies Showing Brexpiprazole Significantly Improved Symptoms of Agitation in Patients with Alzheimer's Dementia at the 2022 Clinical Trials for Alzheimer’s Disease Congress |
- Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder | Otsuka US
- Avanir Pharmaceuticals, Inc. Business Will Be Integrated Into Otsuka America Pharmaceutical, Inc. as of January 1, 2023 | Otsuka US
- View more press releases Close
％sについてのソーシャルメディア
- Otsuka America Pharmaceutical についてのウィキペディア,Google News & Yahoo Financeの記事
- Otsuka America Pharmaceutical についてのLinkedIn,ツイッター & YouTubeの記事
